Can JPM's Strong Q3 Capital Markets Outlook Help Sustain Fee Growth?

JPMorgan expects Q3 2026 investment-banking fees and Markets revenue to each rise in the mid-to-high teens year over year, supported by broad deal activity and strength in fixed income and equities. The outlook follows $3.2B in Q2 IB fees and a record $12.1B in Q2 Markets revenue, implying sequential normalization but continued robust fee income. Higher activity-driven compensation and volume costs could curb operating leverage; consensus expects JPM's 2026 EPS to rise 22.7% to $24.95.

Analysis

The actionable signal is relative, not absolute: JPM’s diversified CIB franchise is converting the current issuance-and-volatility environment into share gains, while BAC’s softer outlook exposes a less favorable mix and raises the risk of downward revisions to its fee-income assumptions. A sustained gap would justify further relative multiple dispersion because JPM’s scale supports balance-sheet financing alongside advisory and trading; that flywheel is difficult for BAC to replicate quickly. C is a more nuanced beneficiary: incremental Markets strength helps, but its valuation remains more dependent on execution against cost, regulatory-remediation and capital-return milestones than on one quarter of revenue.

The near-term risk is that investors capitalize unusually strong Markets revenue as recurring earnings. Trading income is high-beta to realized volatility, client hedging and primary-market calendars; a post-quarter volatility decline or delayed deal closings can produce sequential revenue compression without indicating franchise damage. The more important 6-18 month question is whether JPM can retain incremental revenue after activity normalizes while limiting compensation, technology and balance-sheet costs; failure to expand CIB margins would constrain upside at an already premium tangible-book valuation.

Consensus may be underestimating the negative read-through for BAC rather than the positive read-through for JPM. BAC’s weaker fee trajectory leaves its earnings more exposed to NII expectations, deposit pricing and credit costs just as capital-markets income is becoming a differentiator. Conversely, JPM’s favorable setup is likely well understood; an earnings beat driven solely by Markets, without durable fee backlog conversion or expense discipline, should be sold rather than chased.

Key Decisions for Investors

• Initiate a 1-3 month long JPM / short BAC pair, dollar-neutral, ahead of Q3 results. Target 8-12% relative return; exit if BAC raises fee/trading outlook materially or if JPM signals CIB expense growth that absorbs most incremental revenue.
• Maintain JPM core exposure only through earnings with a tighter risk budget than headline guidance implies; take partial profits on a post-print rally if management does not raise the full-year expense or fee-income outlook. The key falsifier is CIB margin compression despite higher revenue.
• Use C as a selective long only on evidence that Markets strength is accompanied by improved efficiency and capital-return visibility; otherwise prefer JPM for quality. Reassess over the next 1-2 quarters if remediation costs, CET1 needs, or restructuring charges prevent operating leverage.
• Monitor equity issuance calendars, M&A completion data, VIX/MOVE and bank compensation accruals through quarter-end. A sharp decline in volatility or a broad deal-close slippage is an alert to reduce sector-wide capital-markets exposure rather than a reason to add JPM.